Paradox Immunotherapeutics is a pharmaceutical company that develops treatments for patients suffering from rare amyloid diseases.
Paradox Immunotherapeutics has raised $10.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2025.
Paradox Immunotherapeutics's investors include Creative Destruction Lab (CDL), SymBiosis.
Paradox Immunotherapeutics is headquartered in Toronto, Canada.
Paradox Immunotherapeutics is a pharmaceutical company that develops treatments for patients suffering from rare amyloid diseases.
Paradox Immunotherapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Paradox Immunotherapeutics — Funding & Investors." VCBacked, February 25, 2025, https://www.vcbacked.co/company/paradox-immunotherapeutics. Accessed July 19, 2026.
VCBacked. (2025). Paradox Immunotherapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/paradox-immunotherapeutics
{{cite web |title=Paradox Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/paradox-immunotherapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated